Race Oncology Ltd

Race Oncology raises $1.45 million in share placement anchored by biotech investor Daniel Tillett

The funding will be used to advance clinical projects for Race’s cancer drug Bisantrene.

Race Oncology Ltd - Race Oncology raises $1.45 million in share placement anchored by biotech investor Daniel Tillett
Race shares surged more than 27% to 8.3 cents in today’s trading

Race Oncology Ltd (ASX:RAC) has completed a $1.45-million share placement comprising 21.9 million ordinary shares at an issue price of 6.6 cents each.

The placement was anchored by prominent biotech investor Daniel Tillett, who acquired 8.5 million shares worth $561,000 under Race’s 10% placement capacity.

Founder of Sydney-based biotech

Tillett is founder and CEO of Sydney-based biotech Nucleics, a private Australian biotechnology company producing and selling world-leading DNA sequencing software to the genomics industry.

Nucleics software-as-a-service tools are in use in more than 30 countries and more than 250 companies and institutions.

Driving forward value-creating research

Race chief executive officer Peter Molloy said the placement funds would provide Race with the resources needed to drive forward value-creating research and development programs on its cancer drug Bisantrene.

He added: “We now have sufficient funding for at least the current financial year.”

Directors participated in placement

Three current RAC directors also invested a total of $375,000 in the placement, including $250,000 from John Cullity.

Other RAC shareholders invested $510,000, comprising 5 million shares worth $330,000 under the company’s 15% capacity and a further 2.7 million worth $180,000 subject to shareholder approval.

Tillett to join Race board

The issue price represented a 10% premium over the 30-day volume-weighted average price and above the previous close on August 15.

All shares issued will have attached one option for every two shares, exercisable at 9.9 cents on or before August 31, 2021.

After completion of the placement, it is anticipated that Tillett will join the Race board.

Placement anchor Tillet said he was delighted to become involved with Race and looked forward to working with its team.

He said: “I investigated all the public biotechs in Australia and Race came out on top as the company with the most upside and potential.

Pursuing later-stage drug assets

Race’s business model is to pursue later-stage drug assets in the cancer field that have been overlooked by major pharmaceutical companies.

Its first asset is Bisantrene, a chemotherapy drug which was the subject of more than 40 clinical studies during the 1980s and 1990s before being abandoned.

Bisantrene is the subject of two recently granted US patents and third allowed US patent.

Quick facts: Race Oncology Ltd

Price: $0.12

Market: ASX
Market Cap: $11.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Linius Technologies updates from the International...

Linius Technologies Ltd (ASX:LNU) CEO Chris Richardson speaks to Proactive London's Andrew Scott from the International Broadcasting Convention in Amsterdam. ''Linius is here in conjunction with our partner IBM working with them and releasing for the first time the DATN ( digital asset trust...

6 hours, 17 minutes ago

2 min read